VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)

Conditions:   Metastatic Colorectal Cancer;   Colorectal Neoplasms;   Colorectal Carcinoma;   Colorectal Cancer With Hepatic Metastases;   Colorectal Tumors Interventions:   Biological: VB-111;   Drug: Nivolumab Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Conclusion: Our results were not able to show any significant correlation between increasing convenience with QUANTEC limits and lower rectal toxicity. Conclusively, new dosimetric definitions are warranted to predict acute rectal toxicity more accurately in prostate cancer patients during IMRT treatment.
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
Authors: Zhang JJ, Zhang QS, Li ZQ, Zhou JW, Du J Abstract Programmed cell death ligand 1 (PD-L1) is a key suppressor of the cytotoxic immune response. In colorectal carcinoma (CRC), PD-L1 expression results in immune escape and poor prognosis. Extensive researches suggested that metformin had a potential efficacy of enhancing anti-tumor immune response in different types of cancer. However, the detail mechanisms underlying the efficacy in CRC are unclear. Here, we showed that metformin decreases PD-L1 and YAP1 expression in vitro and in vivo. After silencing or inhibiting YAP1 expression by Verteporfin (VP), the i...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
AbstractBackgroundColorectal carcinoma (CRC) is the third most common human cancer. Twist, a basic helix-loop-helix (bHLH) transcription factor, is an epithelial-mesenchymal transition ((EMT) inducer that has been involved in carcinogenesis and chemoresistance. Also, the enhancer of Zeste homolologue2 (EZH2), a member of the polycomb group of genes, had been associated with poor prognosis in several malignancies.ObjectiveTo evaluate the expression of Twist1 and EZH2 in colon carcinoma in Egyptian patients and its relation to clinicopathological parameters, prognosis, and survival.MethodsTwist1 and EZH2 expressions were eva...
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research
Authors: Takeuchi N, Koike K, Yoshida S, Fujiwara M Abstract Recent therapeutic advancements have prolonged the survival duration of patients with metastatic or recurrent colorectal cancer even during salvage treatment. Although treatment with regorafenib and trifluridine/tipiracil combination has exhibited apparent survival benefits, clear and objective evidence of a response to these drugs is scarce. Herein, the present study reports the case of a patient with rectal cancer refractory to multiple surgical interventions and standard chemotherapy. Treatment with regorafenib resulted in immediate improvement of resp...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
ConclusionResults of this study demonstrated the potential of MWL oil in the development of natural anticancer therapeutic agents.Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 22 October 2019Source: Seminars in Cancer BiologyAuthor(s): Tamara T. Lah, Metka Novak, Barbara BreznikAbstractBrain, the major organ of the central nervous system controls and processes most of body activities. Therefore, the most aggressive brain tumor – glioblastoma and metastases from other organs to the brain are lethal leaving the patients with very short time of survival. The brain tissue landscape is very different from any other tissues and the specific microenvironment, comprising stem cells niches and blood-brain barrier, significantly influences the low rate of glioblast...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 6 December 2019Source: Saudi Journal of Biological SciencesAuthor(s): Muhammad Farooq, Nael Abutaha, Shahid Mahboob, Almohannad Baabbad, Nawaf D. Almoutiri, Mohammad Ahmed A.M. WadaanAbstractRecent trends in anticancer therapy is to use therapeutic agents which not only kill the cancer cell, but are less toxic to surrounding normal cells/tissue. One approach is to cut the nutrient supply to growing tumor cells, by blocking the formation of new blood vessels around the tumor. As the phytochemicals and botanical crude extracts have proven their efficacy as natural antiangiogenic agents with...
Source: Saudi Journal of Biological Sciences - Category: Biology Source Type: research
Publication date: Available online 5 December 2019Source: Journal of Organometallic ChemistryAuthor(s): Rianne M. Lord, Jordan Holmes, Frances N. Singer, Abigail Frith, Charlotte E. WillansAbstractA range of precious metal complexes incorporating either benzyl or carbaboranyl functionalised tethered N-heterocyclic carbenes have been prepared, including single X-ray crystallography for one new complex. The library has been screened for their anti-cancer potential against colorectal, ovarian, cisplatin-resistant ovarian and breast cancer cell lines and their selectivity determined by comparing the cytotoxicity towards normal...
Source: Journal of Organometallic Chemistry - Category: Chemistry Source Type: research
CONCLUSIONS The findings from network meta-analysis showed that fruquintinib was associated with significant superiority for PFS and DCR compared with TAS-102, but fruquintinib was associated with significantly increased risk for SAEs compared with regorafenib and TAS-102. PMID: 31790382 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
ConclusionsThe use of regorafenib may not be suitable in patients with a lowCtrough value. To prevent skin toxicities, theCtrough value of M5 should be monitored.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Colorectal Cancer | Research